IBT B — Infant Bacterial Therapeutics AB Share News
0.000.00%
Last trade - 00:00- SEK1.12bn
- SEK1.01bn
Brief: Infant Bacterial Therapeutics Q2 Operating Loss Widens To SEK 30.1 Mln
Brief: Infant Bacterial Therapeutics CFO Leaves The Company
Brief: Infant Bacterial Announces Phase III IBP-9414 Study Results
Brief: Infant Bacterial Therapeutics Q4 Operating Loss SEK 20.5 Mln
Brief: Infant Bacterial Therapeutics Q4 Operating Loss Narrows To SEK 20.54 Mln
Brief: Infant Bacterial Therapeutics Secures Partnership For Production Of Drug Product
Brief: Infant Bacterial Therapeutics Secures Partnership For Production Of Drug Substance
Brief: Infant Bacterial Therapeutics Q3 Operating Loss SEK 48.5 Mln
Brief: Infant Bacterial Therapeutics Q2 Operating Loss Of SEK 20.1 Mln
Brief: Infant Bacterial Therapeutics Q1 Oper Loss At SEK 17.5 Mln
Brief: Infant Bacterial Therapeutics Q4 Operating Income SEK -37.5 Mln
Brief: IBT Continues Development Of Drug Candidate IBP-9414
Brief: Infant Bacterial Therapeutics Q3 Operating Loss Sek 33.8 Mln
Brief: Infant Bacterial Therapeutics Updates On Phase III Study Of IBP-9414
Brief: Infant Bacterial Therapeutics Q2 Operating Loss Widens To SEK 44.3 Mln
Brief: Infant Bacterial Therapeutics's Patent Approved In U.S.
Brief: Infant Bacterial Therapeutics Q1 Oper Loss Widens To SEK 29.8 Mln
Brief: Infant Bacterial Therapeutics Q4 Operating Loss Widens To SEK 45.65 Mln
Brief: Infant Bacterial Therapeutics Q3 Operating Loss Widens To 33,7 Mln